Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 1:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Urinary Tract Clear all
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

NCT03902080
View directory record Official record
Conditions
Overactive Bladder
Interventions
Vibegron, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
45 Years and older · Male only
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
75
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 26, 2026, 1:34 AM EDT
Recruiting Phase 1 Interventional

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

NCT05614739
View directory record Official record
Conditions
Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
Interventions
Vepugratinib, Pembrolizumab, enfortumab vedotin, Trastuzumab Deruxtecan, Midazolam, Digoxin, Rosuvastatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
41
States / cities
Tucson, Arizona • Duarte, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 26, 2026, 1:34 AM EDT
Terminated Not applicable Interventional

The Effects of Sacral Neuromodulation for Urinary Urgency, Frequency, and Urge Incontinence

NCT02776475
View directory record Official record
Conditions
Urinary Urge Incontinence
Interventions
Sacral neuromodulation device turned off
Procedure
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Sep 26, 2026, 1:34 AM EDT
Recruiting No phase listed Observational

Noninvasive Ultrasound Assessment of Detrusor Dysfunction

NCT05652023
View directory record Official record
Conditions
Bladder Dysfunction, Overactive Bladder, BPH With Urinary Obstruction
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
2,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 26, 2026, 1:34 AM EDT
Terminated Early Phase 1 Interventional

GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

NCT03185169
View directory record Official record
Conditions
Genitourinary Abnormality, Breast Cancer Female, Vaginal Abnormality, Urinary Tract Infections, Dyspareunia, Dysuria
Interventions
Replens and coconut oil
Combination Product
Lead sponsor
Alta Bates Summit Medical Center
Other
Eligibility
Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 26, 2026, 1:34 AM EDT
Completed No phase listed Observational

5-Year Objective and Subjective Results of a Mid-Urethral Sling

NCT01657916
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Not listed
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Sep 26, 2026, 1:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

Muscle Fiber Fragment Treatment for Urinary Incontinence

NCT01953263
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Autologous Muscle Fiber Fragments
Other
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 26, 2026, 1:34 AM EDT
Terminated Phase 2 Interventional Results available

S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract

NCT00022633
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
92
States / cities
Mobile, Alabama • Little Rock, Arkansas • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Sep 26, 2026, 1:34 AM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer

NCT00005958
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
12
States / cities
La Jolla, California • Sacramento, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Sep 26, 2026, 1:34 AM EDT
Completed Not applicable Interventional

The Use of Dye-less Cystoscopy in Assessing Urinary Tract Integrity During Hysterectomy

NCT05190939
View directory record Official record
Conditions
Hysterectomy, Cystoscopy
Interventions
water as bladder distending media, intravenous dye, No intervention
Diagnostic Test
Lead sponsor
WellSpan Health
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Sep 26, 2026, 1:34 AM EDT
Completed Phase 1 Interventional

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

NCT02897765
View directory record Official record
Conditions
Urinary Bladder Cancer, Bladder Tumors, Transitional Cell Carcinoma of the Bladder, Malignant Melanoma, Melanoma, Skin Cancer, Carcinoma, Non-Small-Cell Lung, Lung Cancer
Interventions
NEO-PV-01, Nivolumab, Adjuvant
Biological · Other
Lead sponsor
BioNTech US Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Sep 26, 2026, 1:34 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Use of Complementary and Alternative Medicine Among Older Mexican Americans

NCT00084110
View directory record Official record
Conditions
Arthritis, Diabetes Mellitus, Fractures, Hypertension, Depression, Urinary Incontinence
Interventions
Not listed
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
65 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2000
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Sep 26, 2026, 1:34 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

NCT04171700
View directory record Official record
Conditions
Solid Tumor
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Fort Myers, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Sep 26, 2026, 1:34 AM EDT
Completed Phase 2 Interventional

A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder

NCT00321477
View directory record Official record
Conditions
Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Interventions
GW679769 oral tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
41
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 26, 2026, 1:34 AM EDT
Active, not recruiting Not applicable Interventional

To Wipe or Not To Wipe?: That Is The Question

NCT06296901
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Perineal Wipe
Other
Lead sponsor
Joanna A. Orzel
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 26, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study

NCT02793128
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
Interventions
UGN-101 instillations
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
22
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 26, 2026, 1:34 AM EDT
Completed Phase 1 Interventional

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

NCT00004065
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
tanespimycin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 26, 2026, 1:34 AM EDT
Completed Phase 2 Interventional Results available

Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection

NCT00305227
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
Lactin-V, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 26, 2026, 1:34 AM EDT
Active, not recruiting Not applicable Interventional

Butterfly Pivotal Study

NCT05341661
View directory record Official record
Conditions
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
Interventions
Butterfly Prostatic Retraction Device
Device
Lead sponsor
Butterfly Medical Ltd.
Industry
Eligibility
50 Years to 120 Years · Male only
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
3
States / cities
New York, New York • Syosset, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 26, 2026, 1:34 AM EDT
Completed Phase 1 Interventional

Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer

NCT01870037
View directory record Official record
Conditions
Overactive Bladder
Interventions
Placebo (PBS-20% sucrose), hMaxi-K
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Garden City, New York • New York, New York • Poughkeepsie, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 26, 2026, 1:34 AM EDT
Terminated Phase 4 Interventional Results available

Timing of B and O Suppositories to Help Relieve Post-operative Bladder Spasms

NCT02865395
View directory record Official record
Conditions
Overactive Bladder
Interventions
Belladonna and Opium Suppository, Rectal Exam
Drug · Procedure
Lead sponsor
Campbell Grant
Other
Eligibility
18 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Sep 26, 2026, 1:34 AM EDT
Completed Phase 4 Interventional

Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections

NCT00676533
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
Cipro XR (Ciprofloxacin, BAYQ3939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
40
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2013 · Synced Sep 26, 2026, 1:34 AM EDT
Terminated Not applicable Interventional

Moses Vaporization: Is Use of Moses 2.0 in Holmium Laser Ablation of the Prostate More Efficient

NCT04979143
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
Surgical Approach
Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 26, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections

NCT01978938
View directory record Official record
Conditions
cUTI
Interventions
Eravacycline, Levofloxacin
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
San Diego, California • Torrance, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 26, 2026, 1:34 AM EDT